PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 6, 2007, Pages 878-883

  Wieder, Hinrich A ^a   Geinitz, Hans ^a   Rosenberg, Robert ^a   Lordick, Florian ^a   Becker, Karen ^a   Stahl, Alexander ^a   Rummeny, Ernst ^a   Siewert, Jörg R ^a   Schwaiger, Markus ^a   Stollfuss, Jens ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

FLT PET; Proliferation; Rectal cancer; Therapy monitoring

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; FLUOROURACIL; TRACER; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; RECTUM CANCER; ADJUVANT THERAPY; CELL PROLIFERATION; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RECTUM TUMOR; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 34249113173     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0292-2     Document Type: Article

References (25)

1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkan R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
2. Hunerbein M, Pegios W, Rau B, Vogl TJ, Felix R, Schlag PM. Prospective comparison of endorectal ultrasound, three-dimensional endorectal ultrasound, and endorectal MRI in the preoperative evaluation of rectal tumors. Preliminary results. Surg Endosc 2000;14:1005-9.
3. Wallengren NO, Holtas S, Andren-Sandberg A, Jonsson E, Kristoffersson DT, McGill S. Rectal carcinoma: double-contrast MR imaging for preoperative staging. Radiology 2000;215:108-14.
4. Hawnaur JM, Zhu XP, Hutchinson CE. Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancer. Br J Radiol 1998;71:1136-42.
5. Bernini A, Deen KI, Madoff RD, Wong WD. Preoperative adjuvant radiation with chemotherapy for rectal cancer: its impact on stage of disease and the role of endorectal ultrasound. Ann Surg Oncol 1996;3:131-5.
6. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006;33 Suppl 13:27-37.
7. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-90.
8. 18F-FDG. J Nucl Med 2003;44:1426-31.
9. 18F-FDG. J Nucl Med 2005;46:945-52.
10. 18F] 3′-deoxy-3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations-a pilot study. Cancer Biother Radiopharm 2004;19:436-42.
11. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, Novelli M, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602-6.
12. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-94.
13. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695-700.
14. 18F]FLT). J Radioanal Nucl Chem 2000;243:843-6.
15. 11C]methionine positron emission tomography and survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy. Clin Cancer Res 2004;10:1712-64.
16. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-7.
17. Onaitis MW, Noone RB, Hartwig M, Hurwitz H, Morse M, Jowell P, et al. Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. Ann Surg 2001;233:778-85.
18. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30.
19. Mandard AM, Dalibard F, Mandard, JC, Marnay J, Henry-Amar M, Petiot JF. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73:2680-6.
20. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10.
21. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004;45:1754-8.
22. 18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 2006;33:412-9.
23. Pio BS, Park CK, Pietras R, Hsueh W, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8:36-42.
24. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-9.
25. Johansson M, Bergenheim AT, Widmark A, Henriksson R. Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. Br J Cancer 1999;80:142-8.